Frontiers in Cardiovascular Medicine
OCTOBER 9, 2024
ObjectivesThe discovery of pluripotent stem cell-derived cardiomyocytes (PSC-CMs) has not only deepened our understanding of the pathogenesis and progression of heart disease, but also advanced the development of engineered cardiac tissues, cardiac regenerative therapy, drug discovery and the cardiotoxicity assessment of drugs.
DAIC
JANUARY 30, 2025
29, 2025 Researchers atOchsner Health, led byHernan Bazan, MD, DFSVS, FACS, have developed a predictive model with a 93% accuracy rate in determining whether urgent carotid-intervention patients will regain functional independence. tim.hodson Thu, 01/30/2025 - 15:31 Jan.
DAIC
JUNE 4, 2024
In January 2024, the Centers for Medicare and Medicaid Services (CMS) began requiring health care organizations to screen for five social factors: Food insecurity Interpersonal safety Housing insecurity Transportation Utilities The purpose of these screenings is to encourage engagement of community-based organizations with resources to address SDOH.
DAIC
JANUARY 23, 2024
In the hospital setting, CMS increased payment for the FFRCT service by ~7% for 2024. The new code, designated by The American Medical Association ( AMA ), supports FFRCT as the standard of care in assessing patients with suspected coronary artery disease ( CAD ).
CardiacWire
DECEMBER 10, 2023
An international research team used Us2.ai’s with HFpEF) That last part is notable from an echo AI adoption perspective, given that CMS recently approved an outpatient reimbursement code for AI-based HFpEF detection ($285 per use) It could also prove to be notable for Us2.ai, The post Us2.ai’s
Journal of Cardiovascular Pharmacology
SEPTEMBER 12, 2024
Human induced pluripotent stem cells (hiPSC) and atrial hiPSC-derived cardiomyocytes (hiPSC-CM) have entered the arena of preclinical AF research. We believe that the discrepancies indicate that experiments in single atrial CM (both adult atrial CM and atrial hiPSC-CM) might be misleading.
DAIC
MAY 2, 2024
The clinical research results presented for the roll-in cohort from our CardiAMP CMI Trial highlight BioCardia’s continuing efforts to transform the treatment paradigm in refractory angina through the promise of a one-time cost effective minimally invasive autologous cell-based therapy,” said Peter Altman , President and CEO.
Expert insights. Personalized for you.
52 
Let's personalize your content